DataLocalised prostate cancer, intermediate risk

Direct links plus the targets, companies, and technologies of this cancer's products.

• What this page is called in the NHS: Cambridge Prognostic Groups 2 and 3, the two halves of intermediate risk. NICE NG131 1.2.15 defines group 2 as Gleason 3+4=7 (grade group 2) or PSA 10 to 20, at stage T1 to T2, and group 3 as Gleason 3+4=7 and PSA 10 to 20 and stage T1 to T2, or Gleason 4+3=7 (grade group 3) at stage T1 to T2. The split exists because the old three-tier model could not tell 3+4 from 4+3. The treatment differs across the line: in CPG 2 active surveillance, radical prostatectomy and radical radiotherapy are offered as a choice (1.3.9); in CPG 3 radical treatment is offered and active surveillance is only considered for people who choose not to have it (1.3.10). Radiotherapy is combined with six months of androgen deprivation from CPG 2 upwards (1.3.28 and the radical radiotherapy recommendations).
• Within these two groups, two things on the pathology report move a man towards treatment rather than surveillance: the percentage of Gleason pattern 4, a core reporting item in UK core biopsies since October 2024, and the presence of invasive cribriform or intraductal carcinoma, which both ISUP and the Genitourinary Pathology Society treat as a reason to exclude a man from active surveillance.

The same record for scripts and assistants; checked 2026-09-25. Data CC BY-NC 4.0, attribute “Data from OnCo (onco.cc)”.